Megumi Funakoshi-Tago

Prof. Megumi Funakoshi-Tago


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in International Immunopharmacology
Verified
Journal Article
Closed access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
KNKei Nakamura
Kei Nakamura
KTKenji Tago
Kenji Tago
TMTadahiko Mashino
Tadahiko Mashino
TKTadashi Kasahara
Tadashi Kasahara

1 March 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
KOKazuhi Okamoto
Kazuhi Okamoto
RIRika Izumi
Rika Izumi
KTKenji Tago
Kenji Tago
KYKen Yanagisawa
Ken Yanagisawa
HTHiroomi Tamura
Hiroomi Tamura

1 February 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
KTKenji Tago
Kenji Tago
MAMiyuki Abe
Miyuki Abe
YSYoshiko Sonoda
Yoshiko Sonoda
TKTadashi Kasahara
Tadashi Kasahara
It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. Here, to clarify the functional role of the erythropoietin receptor (EpoR) and its downstream transcription factor STAT5 in the abnormal activation of JAK2-induced hematopoietic diseases, we generated a stable transfectant of Ba/F3 cells expressing EpoR and analyzed the molecular mechanism of how JAK2 mutation induces cell growth disorder. JAK2 V617F mutant exhibited transforming activity when EpoR was coexpressed. According to a study utilizing several truncated mutants of EpoR, the ability of EpoR to facilitate the transforming activity of JAK2 V617F mutant required the intracellular domain to interact with STAT5. Strikingly, once the truncated EpoR (EpoR-H) was mutated on Tyr-343, the phosphorylation of which is known to be important for interaction with STAT5, JAK2 V617F mutant failed to exhibit transforming activity, suggesting that STAT5 is critical for JAK2 mutant-induced hematopoietic disorder. Furthermore, the expression of the constitutively active STAT5 mutant exhibited transforming activity in Ba/F3 cells, and short hairpin RNA-mediated knockdown of STAT5 significantly inhibited the transforming activity of JAK2 V617F mutant. Taking these observations together, STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder. Although it remains unclear why the presence of EpoR is required to activate oncogenic signaling via the JAK2 mutant and STAT5, its interacting ability is a target for the treatment of these hematopoietic diseases.

1 February 2011 in Cellular Signalling
Verified
Journal Article
Closed access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
KTKenji Tago
Kenji Tago
YSYoshinori Sato
Yoshinori Sato
STShin-Ichi Tominaga
Shin-Ichi Tominaga
TKTadashi Kasahara
Tadashi Kasahara

1 October 2009 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
STSaeko Tanabe
Saeko Tanabe
KTKenji Tago
Kenji Tago
HIHiroshi Itoh
Hiroshi Itoh
TMTadahiko Mashino
Tadahiko Mashino
TKTadashi Kasahara
Tadashi Kasahara
Glycyrrhiza inflata has been used as a traditional medicine with anti-inflammatory activity; however, its mechanism has not been fully understood. Licochalcone A is a major and biogenetically characteristic chalcone isolated from G. inflata. Here, we found that licochalcone A strongly inhibited tumor necrosis (TNF)-α-induced nuclear localization, DNA binding activity, and the transcriptional activity of nuclear factor-κB (NF-κB). Whereas licochalcone A had no effect on the recruitment of receptor-interacting protein 1 and IκB kinase β (IKKβ) to TNF receptor I by TNF-α, it significantly inhibited TNF-α-induced IκB kinase complex (IKK) activation and inhibitor of nuclear factor-κB degradation. It is interesting that we found that the cysteine residue at position 179 of IKKβ is essential for licochalcone A-induced IKK inhibition, because licochalcone A failed to affect the kinase activity of the IKKβ (C179A) mutant. In contrast, a structurally related compound, echinatin, failed to inhibit TNF-α-induced IKK activation and NF-κB activation, suggesting that the 1,1-dimethy-2-propenyl group in licochalcone A is important for the inhibition of NF-κB. In addition, TNF-α-induced expression of inflammatory cytokines CCL2/monocyte chemotactic protein-1and CXCL1/KC was clearly inhibited by licochalcone A but not echinatin. Taken together, licochalcone A might contribute to the potent anti-inflammatory effect of G. inflata through the inhibition of IKK activation.

1 September 2008 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
TSTaeko Shimizu
Taeko Shimizu
KTKenji Tago
Kenji Tago
MNMotohiro Nakamura
Motohiro Nakamura
HIHiroshi Itoh
Hiroshi Itoh
TKTadashi Kasahara
Tadashi Kasahara